Shots:

• The P-IIIb (ENLIGHTEN-Early) study evaluates Lybalvi vs olanzapine in a ratio (1:1) in 428 adults aged ≥16 & <40yrs. with schizophrenia or bipolar I disorder who were early in the illness
• The study met its pre-specified 1EPs i.e., patients achieved less weight gain @12wks., mean percent change from baseline body weight (6.77% vs 4.91%) & the results were consistent with the (ENLIGHTEN-2) study. In 2EPs, patients gained ≥10% & ≥ 7% baseline body weight @3mos. (21.9% vs 30.4%) & (33.1% vs 44.8%), improvement in symptoms, AEs (63.5% & 63.3%)
• The therapy is approved for schizophrenia & bipolar I disorder as a maintenance monothx. The company plans to submit results to a peer-reviewed journal

Ref: Alkermes | Image: Trading View